Abstract: Disclosed herein are methods for the large-scale production of a highly thermally stable acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). Additionally, the expression methods disclosed herein can produce ChE preparations consisting of extract or purified forms that can be produced in high amounts and are highly thermally stable. These ChE products can be used in vitro detection, detoxification and decontamination methods.

Abstract: Monoclonal antibodies produced in plants at high levels wherein elimination of L chain glycans improves plasma stability of certain plant derived bnAbs are provided. Monoclonal antibodies produced in plants which exhibit no or reduced immunogenicity after multiple injections are provided. Methods of production of the foregoing are provided. Methods of determining immunogenicity assessing the immunogenicity and neutralizing ability of the same are provided. Methods of treating HIV using monoclonal antibodies produced in plants are also provided.

Abstract: Disclosed herein are methods for the large-scale production of a highly thermally stable acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). Additionally, the expression methods disclosed herein can produce ChE preparations consisting of extract or purified forms that can be produced in high amounts and are highly thermally stable. These ChE products can be used in vitro detection, detoxification and decontamination methods.

Abstract: The present invention relates to a treatment by pulmonary delivery of bioscavengers to animals as an effective antidote to prevent toxicity produced by exposure of an animal to nerve agents and other toxic substances.

Abstract: The present invention relates to a treatment by pulmonary delivery of a bioscavenger to animals as an effective antidote to prevent toxicity produced by exposure of an animal to nerve agents and other toxic substances.

Abstract: The present invention relates to a treatment by pulmonary delivery of a bioscavenger to animals as an effective antidote to prevent toxicity produced by exposure of an animal to nerve agents and other toxic substances.

Abstract: The present invention relates to a treatment by pulmonary delivery of bioscavengers to animals as an effective antidote to prevent toxicity produced by exposure of an animal to nerve agents and other toxic substances.

Abstract: Glycoproteins containing high mannose oligosaccharides are obtained and used to generate antibody to the mannose portion of the molecule. Such antibodies can be used in a diagnostic assay. The glycoproteins can be used to generate neutralizing antibody.

Abstract: Gene delivery of a detoxifying agent is described.

Abstract: This application provides a method to produce recombinant bioscavenger molecules to be used as human treatments to protect against toxicity resulting from exposure to chemical/biological agent toxins or drugs. This invention relates to the production of glycoproteins that exhibit poor stability in vivo and are thus inadequate as therapeutic treatments without the additional post-translational modifications of the expressed molecules. In one embodiment, the method combines molecular and biochemical technologies; first for the expression of recombinant molecules and second for the in vitro glycoslyation of the purified or partially purified expressed molecules, intended to mimic the glycoprotein profiles of the native molecules. In another embodiment, post-translation modifications can be provided by direct genetic modification of the cells used in the protein expression system. Although the invention is intended for in vivo use, the invention allows for decontamination in vitro.

Abstract: The present invention relates to a treatment by pulmonary delivery of bioscavengers to animals as an effective antidote to prevent toxicity produced by exposure of an animal to nerve agents and other toxic substances.